Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
Open Access
- 27 April 2015
- journal article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 8 (4) , 387-389
Abstract
Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis. Reduction of spleen volume and improvement of constitutional symptoms and quality of life have been reported as the major findings in sponsored randomized clinical trials. Recent data indicated that the drug improves bone marrow fibrosis and that different targets may be involved in this response. These new data, which require confirmation in prospective trials, may change our perspectives and therapeutic strategies for this disease.Keywords
This publication has 12 references indexed in Scilit:
- Changes in Activated Bone Marrow Macrophages and Mast Cells in Patients with Myelofibrosis Following Ruxolitinib TherapyBlood, 2014
- Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor RuxolitinibBlood, 2014
- Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?Annals of Hematology, 2014
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisBlood, 2013
- Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinibHaematologica, 2013
- Efficacy and safety of pegylated‐interferon α‐2a in myelofibrosis: a study by the FIM and GEM French cooperative groupsBritish Journal of Haematology, 2013
- Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaHaematologica, 2012
- Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012British Journal of Haematology, 2012
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012
- Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary reportBlood, 2011